2024-09-12 08:38:29 ET
Summary
- Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma and a boxed warning for cytokine release syndrome.
- The U.S. population eligible for Tecelra is small, approximately 100-400 patients, based on various eligibility factors.
- The collaboration with Galapagos provides $70 million upfront and potential milestone payments up to $465 million, expanding the development of uza-cel in solid tumors.
- Adaptimmune’s Q2 2024 revenue jumped due to deferred revenue from the terminated Genentech collaboration, resulting in a $69.5 million net profit.
- Given the limited market and logistical complexities, the likelihood of peak revenue exceeding $200 million is low, presenting high investment risk.
Introduction
Adaptimmune Therapeutics ( ADAP ) is advancing T-cell receptor (TCR) therapies for the treatment of solid tumors. Their pipeline has three main candidates, including afamitresgene autoleucel (afami-cel), letetresgene autoleucel (lete-cel), and uza-cel. They are also advancing preclinical programs targeting PRAME and CD70 for various solid and hematological malignancies....
Read the full article on Seeking Alpha
For further details see:
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
